MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA

American Journal of Cancer Research

Volumn 6, Issue 8, 2016, Pages 1695-1707

  Liang, Haiqian ^a,b   Wang, Renjie ^a   Jin, Ying ^a   Li, Jianwei ^a   Zhang, Sai ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Chinese Glioma Cooperative Group (CGCG)   (China)

Author keywords

GBM; microRNA; miR 422a; PIK3CA

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA; MICRORNA 422A; PHOSPHATIDYLINOSITOL 4,5 BIPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PHOSPHATIDYLINOSITOL 4,5 BIPHOSPHATE 3 KINASE CATALYTIC SUBUNIT GAMMA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PYRUVATE DEHYDROGENASE KINASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CHROMOSOME 2; CHROMOSOME 3; CHROMOSOME 7; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WOUND HEALING;

EID: 85000352001     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Easaw JC, Mason WP, Perry J, Laperriere N, Eisenstat DD, Del Maestro R, Belanger K, Fulton D, Macdonald D; Canadian Glioblastoma Recommendations Committee. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 2011; 18: e126-136.
2. Kovic B and Xie F. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol 2015; 33: 2296-2302.
3. Lee JK, Chang N, Yoon Y, Yang H, Cho H, Kim E, Shin Y, Kang W, Oh YT, Mun GI, Joo KM, Nam DH and Lee J. USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. Neuro Oncol 2016; 18: 37-47.
4. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB and Hudson BG. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363: 343-354.
5. Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol 2016; 128: 157-62.
6. Nichol D and Mellinghoff IK. PI3K pathway inhibition in GBM-is there a signal? Neuro Oncol 2015; 17: 1183-1184.
7. Lee II, Maniar K, Lydon JP and Kim JJ. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. Oncogene 2016; [Epub ahead of print].
8. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
9. Luo W and Sehgal A. Regulation of circadian behavioral output via a MicroRNA-JAK/STAT circuit. Cell 2012; 148: 765-779.
10. Devor EJ, Schickling BM, Reyes HD, Warrier A, Lindsay B, Goodheart MJ, Santillan DA and Leslie KK. Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182. Oncol Rep 2016; 35: 2461-2465.
11. Hong L, Ya-Wei L, Hai W, Qiang Z, Jun-Jie L, Huang A, Song-Tao Q, Yun-Tao L. MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway. J Neurooncol 2016; 128: 35-45.
12. Teplyuk NM, Uhlmann EJ, Gabriely G, Volfovsky N, Wang Y, Teng J, Karmali P, Marcusson E, Peter M, Mohan A, Kraytsberg Y, Cialic R, Chiocca EA, Godlewski J, Tannous B and Krichevsky AM. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med 2016; 8: 268-287.
13. Qiu S, Lin S, Hu D, Feng Y, Tan Y and Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 2013; 11: 10.
14. Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget 2015; 6: 29413-29427.
15. Skalsky RL and Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One 2011; 6: e24248.
16. Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer 2014; 33: 1-3.
17. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
18. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
19. Zhang J, Yang Y, Yang T, Yuan S, Wang R, Pan Z, Yang Y, Huang G, Gu F, Jiang B, Lin C and Zhou W. Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis. Hepatology 2015; 61: 561-573.
20. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R and Slaby O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-2666.
21. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY and Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 2011; 129: 680-690.
22. Zheng G, Du L, Yang X, Zhang X, Wang L, Yang Y, Li J and Wang C. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer 2014; 111: 1985-1992.
23. Wang L, Liu M, Zhu H, Rong W, Wu F, An S, Liu F, Feng L, Wu J and Xu N. Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy. Cancer Biol Ther 2015; 16: 1445-1452.
24. Liang S, Chen L, Huang H and Zhi D. The experimental study of miRNA in pituitary adenomas. Turk Neurosurg 2013; 23: 721-727.
25. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
26. Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, Kageji T and Nagahiro S. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 2010; 12: 221-232.
27. Lefranc F, Brotchi J and Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005; 23: 2411-2422.